

Emmanouil Tsochatzis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/33131/emmanouil-tsochatzis-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

289
papers

11,231
citations

48
h-index

100
g-index

407
ext. papers

14,775
ext. citations

5.7
avg, IF

6.96
L-index

#	Paper	IF	Citations
289	The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma.. <i>The Cochrane Library</i> , 2022 , 1, CD013345	5.2	2
288	Assessment of clinically significant portal hypertension by two-dimensional shear wave elastography.. <i>European Journal of Clinical Investigation</i> , 2022 , e13750	4.6	0
287	Metabolic Complications Before and After Liver Transplantation 2022 , 357-371		
286	Translation Reprogramming as a Novel Therapeutic Target in MAFLD.. <i>Advanced Biology</i> , 2022 , e2101298		0
285	Prognostic Factors for 10-Year Survival in Patients With Hepatocellular Cancer Receiving Liver Transplantation.. <i>Frontiers in Oncology</i> , 2022 , 12, 877107	5.3	0
284	Biomarkers for brain injury and copper toxicity in Wilson's disease: a diffusion tensor imaging study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 , 93, A94.1-A94	5.5	
283	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. <i>American Journal of Gastroenterology</i> , 2021 , 116, 723-732	0.7	25
282	Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update". <i>Journal of Hepatology</i> , 2021 ,	13.4	
281	Epidemiology of Varices and Variceal Bleeding in Liver Cirrhosis 2021 , 1-11		1
280	Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. <i>PLoS ONE</i> , 2021 , 16, e0260313	3.7	2
279	Non-alcoholic fatty liver disease: Current therapeutic options. <i>Current Opinion in Pharmacology</i> , 2021 , 61, 98-105	5.1	3
278	Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. <i>Journal of Hepatology</i> , 2021 ,	13.4	3
277	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
276	Response to Anand and Sharma. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1094-1095	0.7	
275	Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2184-e2193	11.6	5
274	Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2021 , 3, CD013122	5.2	5
273	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 185-198	18.8	36

272	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. <i>European Journal of Health Economics</i> , 2021 , 22, 505-518	3.6	3
271	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021 , 41, 1227-1242	7.9	20
270	Case-finding strategies in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2021 , 3, 100219	10.3	7
269	Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2021 , 4, CD013121	5.2	3
268	Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2021 , 4, CD013155	5.2	4
267	Histological sub-classification of cirrhosis using collagen proportionate area in patients with chronic hepatitis C. <i>Liver International</i> , 2021 , 41, 1608-1613	7.9	1
266	Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis. <i>The Cochrane Library</i> , 2021 , 6, CD013156	5.2	2
265	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 717-729	24.2	16
264	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. <i>The Cochrane Library</i> , 2021 , 7, CD013157	5.2	2
263	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. <i>Movement Disorders</i> , 2021 , 36, 503-508	7	5
262	Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2021 , 74, 1109-1116	13.4	39
261	Royal Free Hospital-estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. <i>Liver International</i> , 2021 , 41, 819-827	7.9	0
260	Establishing Reliability Criteria for Liver ElastPQ Shear Wave Elastography (ElastPQ-SWE): Comparison Between 10, 5 and 3 Measurements. <i>Ultraschall in Der Medizin</i> , 2021 , 42, 204-213	3.8	7
259	Reply to: "Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD" and "Transient elastography in chronic liver disease: Beware of the cut-offs!". <i>Journal of Hepatology</i> , 2021 , 75, 1247	13.4	
258	Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 1013-1025	6.1	8
257	Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?" <i>Journal of Hepatology</i> , 2021 , 75, 752-753	13.4	
256	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. <i>Hepatology</i> , 2021 ,	11.2	8
255	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. <i>Journal of Hepatology</i> , 2021 , 75, 659-689	13.4	102

254	NAFLD: Diagnostic Algorithms for Regulating Patient Fluxes. <i>Current Pharmaceutical Design</i> , 2021 , 27, 3036-3046	3.3	1
253	Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?. <i>Gut</i> , 2021 ,	19.2	1
252	Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. <i>Hepatology Communications</i> , 2021 , 5, 1824-1832	6	3
251	Treatment of severe alcoholic hepatitis: A systematic review. <i>Current Opinion in Pharmacology</i> , 2021 , 60, 91-101	5.1	0
250	Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)". <i>Journal of Hepatology</i> , 2021 , 74, 248-249	13.4	
249	Response to Debnath and Rathi. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1358-1359	0.7	
248	The Role of Transient Elastography for Fibrosis Staging in HCV-Related Chronic Liver Disease 2021 , 27-42		
247	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2021 ,	13.4	7
246	Natural history of NAFLD: knowns and unknowns. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	1
245	Bacterial infections correlate with poor prognosis in cirrhosis independently from liver disease severity. <i>Journal of Hepatology</i> , 2020 , 73, S737-S738	13.4	
244	Sarcopenia Does Not Worsen Survival in Patients With Cirrhosis Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1911-1914	0.7	18
243	Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020 , 111S, 154291	12.7	7
242	New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. <i>Hepatology</i> , 2020 , 71, 1831-1844	11.8	10
241	Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis. <i>The Cochrane Library</i> , 2020 , 1, CD013203	5.2	6
240	Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2020 , 1, CD013123	5.2	5
239	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020 , 72, 1140-1150	13.4	41
238	Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020 , 2020, 9181368	2.8	20
237	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 362-373	18.8	151

236	Reply to: "FIB-4 cut off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , 2020 , 73, 217-218	13.4	1
235	Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. <i>Gut</i> , 2020 , 69, 1173-1192	19.2	59
234	Collagen proportionate area predicts clinical outcomes in patients with alcohol-related liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1728-1739	6.1	4
233	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020 , 29, 235-245	1.4	9
232	Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4CD25FoxP3 regulatory T cells activation. <i>Theranostics</i> , 2020 , 10, 910-924	12.1	20
231	Tacrolimus Trough Concentrations After Liver Transplantation: Back to the Future. <i>Transplantation</i> , 2020 , 104, e114	1.8	
230	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. <i>Metabolism: Clinical and Experimental</i> , 2020 , 113, 154413	12.7	16
229	Elastic fibres in alcoholic liver disease. <i>Scientific Reports</i> , 2020 , 10, 20098	4.9	1
228	Curve Your Enthusiasm: The Decision to Use Expanded or Original Baveno VI Criteria to Exclude High-Risk Varices. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1243-1244	6.9	3
227	Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study. <i>Hepatology</i> , 2020 , 71, 627-642	11.2	16
226	Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. <i>Hepatology</i> , 2020 , 71, 569-582	11.2	17
225	Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2020 , 1, CD013125	5.2	8
224	Management of metabolic syndrome and cardiovascular risk after liver transplantation. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 731-741	18.8	11
223	Cardiovascular morbidity and mortality is increased post-liver transplantation even in recipients with no pre-existing risk factors. <i>Liver International</i> , 2019 , 39, 1557-1565	7.9	6
222	The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation. <i>Liver Transplantation</i> , 2019 , 25, 1023-1033	4.5	10
221	Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1214-1222	6.1	28
220	Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019 , 39, 1325-1334	7.9	23
219	Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019 , 71, 371-378	13.4	141

218	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019 , 156, 1717-1730	13.3	356
217	Top research priorities in liver and gallbladder disorders in the UK. <i>BMJ Open</i> , 2019 , 9, e025045	3	13
216	Incidence and outcome of colorectal cancer in liver transplant recipients: A national, multicentre analysis on 8115 patients. <i>Liver International</i> , 2019 , 39, 353-360	7.9	7
215	Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes non-alcoholic fatty liver disease-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 339	6.1	1
214	Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2019 , 19, 122	3	36
213	Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis. <i>Liver International</i> , 2019 , 39, 2052-2060	7.9	27
212	SAT-016-Impact of sarcopenia in patients undergoing transjugular intrahepatic portosystemic shunt insertion for refractory ascites. <i>Journal of Hepatology</i> , 2019 , 70, e632	13.4	3
211	Effect of acute upper gastrointestinal bleeding manifestations at admission on the in-hospital outcomes of liver cirrhosis: hematemesis versus melena without hematemesis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 1334-1341	2.2	7
210	Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2019 , 9, CD013120	5.2	5
209	Glucocorticosteroids for people with alcoholic hepatitis. <i>The Cochrane Library</i> , 2019 , 4, CD001511	5.2	7
208	Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2019 , 9, CD013103	5.2	23
207	Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation. <i>Aids</i> , 2019 , 33, 805-814	3.5	11
206	Etiology and Severity of Liver Disease in HIV-Positive Patients With Suspected NAFLD: Lessons From a Cohort With Available Liver Biopsies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 80, 474-480	3.1	10
205	Area Under Trough Concentrations of Tacrolimus as a Predictor of Progressive Renal Impairment After Liver Transplantation. <i>Transplantation</i> , 2019 , 103, 2539-2548	1.8	7
204	Human Immunodeficiency Virus and Fatty Liver: The Perfect Storm or a Storm in a Teacup?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 81, e25-e26	3.1	
203	International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. <i>Transplantation</i> , 2019 , 103, 45-56	1.8	42
202	Predictors of Re-bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS). <i>Digestive Diseases and Sciences</i> , 2019 , 64, 1335-1345	4	29
201	Comparison and correlation of fibrosis stage assessment by collagen proportionate area (CPA) and the ELF panel in patients with chronic liver disease. <i>Digestive and Liver Disease</i> , 2019 , 51, 1001-1007	3.3	5

200	Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2019 , 114, 446-452	0.7	42
199	Investigation and management of a raised serum ferritin. <i>British Journal of Haematology</i> , 2018 , 181, 331-340	3.4	61
198	The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). <i>Hormones</i> , 2018 , 17, 219-229	3.1	31
197	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018 , 154, 1694-1705.e4	13.3	90
196	The Royal Free Hospital 'hub-and-spoke network model' delivers effective care and increased access to liver transplantation. <i>Public Health</i> , 2018 , 154, 164-171	4	11
195	MAIT cells are chronically activated in patients with autoimmune liver disease and promote profibrogenic hepatic stellate cell activation. <i>Hepatology</i> , 2018 , 68, 172-186	11.2	76
194	Elastography methods for the non-invasive assessment of portal hypertension. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 155-164	4.2	38
193	Establishing reliability criteria for Liver ElastPQ Shear-wave Elastography (ElastPQ-SWE): Comparison between 3,5 and 10 measurements. <i>Journal of Hepatology</i> , 2018 , 68, S554-S555	13.4	3
192	Non-alcoholic fatty liver disease and the interface between primary and secondary care. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 509-517	18.8	64
191	The use of statins in the management of chronic liver disease. <i>AME Medical Journal</i> , 2018 , 3, 3-3	1	
190	Pharmacological interventions for acute hepatitis C infection. <i>The Cochrane Library</i> , 2018 , 12, CD011644	5.2	0
189	Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2018 ,	5.2	19
188	Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2018 ,	5.2	2
187	Primary prevention of bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2018 ,	5.2	2
186	Secondary prevention of bleeding in people with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2018 ,	5.2	1
185	Treatment for ascites in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2018 ,	5.2	1
184	Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2018 ,	5.2	1
183	Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2018 ,	5.2	2

182	Lifestyle modifications for non-alcohol related fatty liver disease: a network meta-analysis. <i>The Cochrane Library</i> , 2018 ,	5.2	2
181	Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis. <i>The Cochrane Library</i> , 2018 ,	5.2	1
180	Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017 , 8, 113-121	10.3	160
179	Diagnosis and treatment of ascites. <i>Journal of Hepatology</i> , 2017 , 67, 184-185	13.4	16
178	Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity. <i>American Journal of Gastroenterology</i> , 2017 , 112, 588-596	0.7	62
177	Current and future treatment options in non-alcoholic steatohepatitis (NASH). <i>Expert Review of Gastroenterology and Hepatology</i> , 2017 , 11, 357-369	4.2	26
176	Interventions for hereditary haemochromatosis: an attempted network meta-analysis. <i>The Cochrane Library</i> , 2017 , 3, CD011647	5.2	4
175	Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. <i>The Cochrane Library</i> , 2017 , 3, CD011649	5.2	13
174	Transaminase abnormalities and adaptations of the liver lobule manifest at specific cut-offs of steatosis. <i>Scientific Reports</i> , 2017 , 7, 40977	4.9	10
173	Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 1363-1372	4	3
172	Reply to: "The BAVENO VI criteria to identify patients not requiring endoscopic surveillance for esophageal varices - Should We use it?". <i>Journal of Hepatology</i> , 2017 , 66, 1332-1333	13.4	
171	Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis. <i>The Cochrane Library</i> , 2017 , 3, CD011343	5.2	17
170	An objective definition for clinical suspicion of T-cell-mediated rejection after liver transplantation. <i>Clinical Transplantation</i> , 2017 , 31, e13005	3.8	7
169	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. <i>Frontline Gastroenterology</i> , 2017 , 8, 252-259	2.6	15
168	Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis. <i>The Cochrane Library</i> , 2017 , 3, CD011650	5.2	45
167	Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. <i>The Cochrane Library</i> , 2017 , 3, CD011639	5.2	23
166	Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease): an attempted network meta-analysis. <i>The Cochrane Library</i> , 2017 , 3, CD011646	5.2	7
165	Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis. <i>The Cochrane Library</i> , 2017 , 3, CD011645	5.2	7

164	Gender differences in liver disease and the drug-dose gender gap. <i>Pharmacological Research</i> , 2017 , 120, 97-108	10.2	35
163	Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. <i>The Cochrane Library</i> , 2017 , 3, CD011640	5.2	28
162	Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. <i>The Cochrane Library</i> , 2017 , 3, CD011648	5.2	8
161	Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis. <i>The Cochrane Library</i> , 2017 , 3, CD011644	5.2	1
160	Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites. <i>Liver International</i> , 2017 , 37, 1334-1344	7.9	24
159	Glucocorticosteroids for people with alcoholic hepatitis. <i>The Cochrane Library</i> , 2017 , 11, CD001511	5.2	8
158	Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease. <i>Minerva Endocrinology</i> , 2017 , 42, 184-194	2.5	13
157	Downstaging for hepatocellular cancer: harm or benefit?. <i>Translational Gastroenterology and Hepatology</i> , 2017 , 2, 106	5.2	17
156	Surrogate endpoints for clinical trials in non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 549-550	18.8	2
155	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. <i>Journal of Hepatology</i> , 2017 , 66, S593	13.4	7
154	Reply. <i>Hepatology</i> , 2017 , 66, 1361-1362	11.2	0
153	Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. <i>Hepatology</i> , 2017 , 66, 1980-1988	11.2	150
152	Validation of the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease: an individual patient meta-analysis. <i>Journal of Hepatology</i> , 2017 , 66, S69	13.4	2
151	Bleeding Risk with Invasive Procedures in Patients with Cirrhosis and Coagulopathy. <i>Current Gastroenterology Reports</i> , 2017 , 19, 45	5	18
150	Rifaximin treatment for encephalopathy reduces hospital resource use: real-world data don't fail to IMPRESS. <i>Frontline Gastroenterology</i> , 2017 , 8, 230-231	2.6	1
149	Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. <i>Hepatology</i> , 2017 , 66, 1910-1919	11.2	65
148	Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: The royal free hospital cirrhosis glomerular filtration rate. <i>Hepatology</i> , 2017 , 65, 582-591	11.2	32
147	MRE in NAFLD: Promising but Further Validation is Required. <i>Annals of Hepatology</i> , 2017 , 16, 331-332	3.1	

146	Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. <i>Annals of Translational Medicine</i> , 2017 , 5, 40	3.2	49
145	Liver test abnormalities in patients with HIV mono-infection: assessment with simple noninvasive fibrosis markers. <i>Annals of Gastroenterology</i> , 2017 , 30, 349-356	2.2	10
144	Glucocorticosteroids for people with alcoholic hepatitis. <i>The Cochrane Library</i> , 2016 ,	5.2	3
143	FibroTest, transient elastography method, and combined FibroTest and transient elastography method for diagnosis of severe hepatic fibrosis and cirrhosis in adults with chronic hepatitis C. <i>The Cochrane Library</i> , 2016 ,	5.2	1
142	Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. <i>Digestive and Liver Disease</i> , 2016 , 48, 1471-1477	3.3	35
141	Case 21-2016: A Man in an Unresponsive State. <i>New England Journal of Medicine</i> , 2016 , 375, 1697	59.2	
140	Emerging hepatic syndromes: pathophysiology, diagnosis and treatment. <i>Internal and Emergency Medicine</i> , 2016 , 11, 905-16	3.7	5
139	The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). <i>Metabolism: Clinical and Experimental</i> , 2016 , 65, 1038-48	12.7	1227
138	Systematic review with meta-analysis: diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 575-85	6.1	42
137	Subtypes and clinical significance of common bile duct varices in portal vein thrombosis: diagnosis and follow-up by Doppler US and EUS. <i>Abdominal Radiology</i> , 2016 , 41, 476-84	3	3
136	EASL Clinical Practice Guidelines: Liver transplantation. <i>Journal of Hepatology</i> , 2016 , 64, 433-485	13.4	484
135	Biomarkers of bacterial translocation in advanced chronic liver disease: the key to individualizing prognosis. <i>Annals of Gastroenterology</i> , 2016 , 29, 1-2	2.2	6
134	Defining Clinical Hints to Predict Decompensation and Altering Paradigm in Patients with Cirrhosis 2016 , 89-97		
133	Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 786-91	2.2	11
132	Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. <i>Transplant International</i> , 2016 , 29, 961-73	3	31
131	Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease. <i>The Cochrane Library</i> , 2016 , 3, CD011602	5.2	13
130	Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. <i>Journal of Hepatology</i> , 2016 , 65, 899-905	13.4	126
129	The clinical utility of noninvasive blood tests and elastography 2016 , 124-130		

128	Implications and benefits of the use of rifaximin for preventing episodes of hepatic encephalopathy. <i>British Journal of Health Care Management</i> , 2016 , 22, 108-111	0.4	1
127	Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016 , 12, 61-9	1.9	29
126	Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 139-49	3.4	14
125	Lack of agreement for defining 'clinical suspicion of rejection' in liver transplantation: a model to select candidates for liver biopsy. <i>Transplant International</i> , 2015 , 28, 455-64	3	20
124	Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. <i>The Cochrane Library</i> , 2015 , 1, CD010542	5.2	43
123	Hepascore and hyaluronic acid as markers of fibrosis in liver disease of mixed aetiology. <i>European Journal of Gastroenterology and Hepatology</i> , 2015 , 27, 313-20	2.2	8
122	Global Epidemiology of Hepatitis B Virus (HBV) Infection. <i>Current Hepatology Reports</i> , 2015 , 14, 171-178	1	26
121	Ultrasonography for diagnosis of cirrhosis in people with alcoholic liver disease 2015 ,		10
120	Forns index and 'FIB4' for staging of fibrosis in adults with chronic hepatitis C. <i>The Cochrane Library</i> , 2015 ,	5.2	2
119	PWE-085 Analysis of new patient attendances for nafld at three london hospitals highlights the need to develop clinical risk stratification pathways. <i>Gut</i> , 2015 , 64, A249.1-A249	19.2	
118	PWE-097 Pharmacological treatments for primary sclerosing cholangitis: a network meta-analysis. <i>Gut</i> , 2015 , 64, A254.2-A255	19.2	
117	PTH-119 Differences between radiology and histopathology: are we judging wrong? should we lower alpha-fetoprotein cut-off in the selection criteria?. <i>Gut</i> , 2015 , 64, A460.1-A460	19.2	1
116	Expansion of Access to HBV Treatment. <i>Current Hepatology Reports</i> , 2015 , 14, 195-202	1	
115	Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease): a network meta-analysis 2015 ,		1
114	Assessing liver disease in HIV-HCV coinfectd patients. <i>Current Opinion in HIV and AIDS</i> , 2015 , 10, 316-224	2	8
113	Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11044-52	5.6	22
112	Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>International Journal of Endocrinology</i> , 2015 , 2015, 343828	2.7	32
111	Letter: scoring models in alcoholic hepatitis - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 127	6.1	0

110	PTH-134 Reduced calcineurin inhibitor exposure early after liver transplantation protects against renal dysfunction independently of the use of basiliximab induction therapy. <i>Gut</i> , 2015 , 64, A467.2-A467 ^{19,2}		
109	Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. <i>Journal of Hepatology</i> , 2015 , 63, 1139-46	13.4	71
108	Metabolic and cardiovascular complications in the liver transplant recipient. <i>Annals of Gastroenterology</i> , 2015 , 28, 183-192	2.2	27
107	Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015 , 19, 1-409, v-vi	4.4	101
106	Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 3020-9	5.6	30
105	Cost-effectiveness of upcoming treatments for hepatitis C: we need to get the models right. <i>Journal of Hepatology</i> , 2014 , 61, 453-4	13.4	2
104	Liver cirrhosis. <i>Lancet, The</i> , 2014 , 383, 1749-61	40	1021
103	Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 721-32	6.1	38
102	Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. <i>Hepatology</i> , 2014 , 60, 832-43	11.2	48
101	Beta-blockers in cirrhosis: therapeutic window or an aspirin for all?. <i>Journal of Hepatology</i> , 2014 , 61, 449-504	5.4	10
100	Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis. <i>Journal of Hepatology</i> , 2014 , 60, 948-54	13.4	95
99	Inflammation-based scores and hepatocellular carcinoma. <i>Liver Transplantation</i> , 2014 , 20, 1529-30	4.5	1
98	Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3069-77	5.6	52
97	Embolization of porto-systemic shunt as treatment for recurrent hepatic encephalopathy. <i>Annals of Hepatology</i> , 2014 , 13, 555-557	3.1	2
96	Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. <i>Gut</i> , 2014 , 63, 1005-13	19.2	16
95	Prognosis and treatment of patients with acute alcoholic hepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014 , 8, 471-86	4.2	8
94	Future treatments of cirrhosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014 , 8, 571-81	4.2	18
93	Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria. <i>Liver Transplantation</i> , 2014 , 20, 1327-35	4.5	33

92	Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. <i>Liver International</i> , 2014 , 34, 1452-63	7.9	45
91	Letter: Prognostic scores in alcoholic hepatitis--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1341	6.1	1
90	Is MELD the best prognostic score in acute variceal bleeding? The jury is still out. <i>Annals of Gastroenterology</i> , 2014 , 27, 282-283	2.2	1
89	ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2014 , 3, 415-8	2.1	8
88	Embolization of porto-systemic shunt as treatment for recurrent hepatic encephalopathy. <i>Annals of Hepatology</i> , 2014 , 13, 555-7	3.1	2
87	Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. <i>Journal of Hepatology</i> , 2013 , 58, 262-70	13.4	77
86	A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2013 , 108, 1252-9	8.7	99
85	Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 1354-64	6.1	25
84	Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. <i>The Cochrane Library</i> , 2013 , CD006573	5.2	6
83	Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus. <i>The Cochrane Library</i> , 2013 , CD006803	5.2	5
82	Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization. <i>Journal of Hepatology</i> , 2013 , 58, 194	13.4	3
81	HCV in liver transplantation. <i>Seminars in Immunopathology</i> , 2013 , 35, 101-10	12	10
80	Transarterial chemoembolisation is not superior to embolisation alone: the recent European Association for the Study of the Liver (EASL) - European Organisation for Research and Treatment of Cancer (EORTC) guidelines. <i>European Journal of Cancer</i> , 2013 , 49, 1509-10	7.5	21
79	Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. <i>Journal of Hepatology</i> , 2013 , 58, 962-8	13.4	48
78	25 LONG TERM 18 YEAR FOLLOW UP OF A RANDOMIZED TRIAL OF TACROLIMUS MONOTHERAPY VERSUS TRIPLE THERAPY AFTER LIVER TRANSPLANTATION FOR HCV CIRRHOSIS. <i>Journal of Hepatology</i> , 2013 , 58, S11	13.4	3
77	Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013 , 59, 1193-9	13.4	132
76	Sample size requirement for digital image analysis of collagen proportionate area in cirrhotic livers. <i>Histopathology</i> , 2013 , 62, 421-30	7.3	24
75	Reducing early exposure to calcineurin inhibitors: the key factor for a successful renal sparing strategy. <i>American Journal of Transplantation</i> , 2013 , 13, 239	8.7	7

74	Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy. <i>BioMed Research International</i> , 2013 , 2013, 139763	3	7
73	Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long. <i>American Journal of Transplantation</i> , 2013 , 13, 1371-2	8.7	7
72	Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. <i>Liver International</i> , 2013 , 33, 944-9	7.9	43
71	PWE-166 Hepatic Artery Embolisation in Neuroendocrine Tumors; Outcomes From a Series of 50 Patients. <i>Gut</i> , 2013 , 62, A198.1-A198	19.2	
70	Transarterial therapies for hepatocellular carcinoma. <i>Recent Results in Cancer Research</i> , 2013 , 190, 195-206	10.5	13
69	Liver stiffness measurements increase after meal ingestion--an important step towards standardization. <i>Annals of Hepatology</i> , 2013 , 12, 839-40	3.1	1
68	Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. <i>American Journal of Transplantation</i> , 2012 , 12, 2797-814	8.7	108
67	Predicting severity and clinical course of acute rejection after liver transplantation using blood eosinophil count. <i>Transplant International</i> , 2012 , 25, 555-63	3	40
66	Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012 , 27, 1227-32	4	50
65	New therapeutic paradigm for patients with cirrhosis. <i>Hepatology</i> , 2012 , 56, 1983-92	11.2	94
64	Regression of fibrosis: the need for quantitative methods of assessment. <i>Journal of Hepatology</i> , 2012 , 57, 1391; author reply 1392	13.4	4
63	Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. <i>Liver International</i> , 2012 , 32, 919-27	7.9	231
62	Renal failure and cirrhosis: a systematic review of mortality and prognosis. <i>Journal of Hepatology</i> , 2012 , 56, 810-8	13.4	187
61	Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. <i>Journal of Hepatology</i> , 2012 , 57, 288-96	13.4	176
60	Adrenocortical dysfunction in liver disease: a systematic review. <i>Hepatology</i> , 2012 , 55, 1282-91	11.2	86
59	Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 634-46	6.1	33
58	Hepatocellular carcinoma. <i>New England Journal of Medicine</i> , 2012 , 366, 92; author reply 92-3	59.2	49
57	Non-invasive assessment of liver fibrosis. <i>Annals of Gastroenterology</i> , 2012 , 25, 218-231	2.2	75

56	Elastography for hepatic fibrosis severity in chronic hepatitis B or C. <i>Case Reports in Gastroenterology</i> , 2011 , 5, 63-72	1	2
55	Assessment of adrenocortical reserve in stable patients with cirrhosis. <i>Journal of Hepatology</i> , 2011 , 54, 243-50	13.4	54
54	Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. <i>Journal of Hepatology</i> , 2011 , 54, 650-9	13.4	508
53	Is there any progress in the treatment of non-alcoholic fatty liver disease?. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2011 , 2, 1-5	3	11
52	Long-term follow-up of immunosuppressive monotherapy in liver transplantation: tacrolimus and microemulsified cyclosporin. <i>Clinical Transplantation</i> , 2011 , 25, 614-24	3.8	15
51	Does MMF really slow down fibrosis of HCV recurrence in liver transplant recipients?. <i>Transplant International</i> , 2011 , 24, e77-8	3	1
50	Primary prevention of variceal hemorrhage. <i>Current Gastroenterology Reports</i> , 2011 , 13, 3-9	5	3
49	Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. <i>Liver Transplantation</i> , 2011 , 17, 178-88	4.5	62
48	Noninvasive assessment of liver fibrosis: the need for better validation. <i>Hepatology</i> , 2011 , 53, 1781-2; author reply 1782-3	11.2	9
47	Noninvasive assessment of liver fibrosis: the clinical context and question are important. <i>Hepatology</i> , 2011 , 54, 2276	11.2	8
46	Validating non-invasive markers of fibrosis: the need for a new histological reference standard. <i>Gut</i> , 2011 , 60, 1442-3; author reply 1443-4	19.2	10
45	Systematic review: portal vein thrombosis in cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 366-74	6.1	207
44	Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 573-82	6.1	6
43	Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 800-6	3.4	40
42	Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review. <i>Transplant International</i> , 2010 , 23, 861-70	3	36
41	Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. <i>Gastroenterology</i> , 2010 , 139, 1246-56, 1256.e1-5	13.3	703
40	Prolonging survival in patients with cirrhosis: old drugs with new indications. <i>Gastroenterology</i> , 2010 , 139, 1813-1815.e1	13.3	20
39	Which transarterial therapy is best for hepatocellular carcinoma?--the evidence to date. <i>Journal of Hepatology</i> , 2010 , 53, 588	13.4	12

38	Primary prevention of variceal haemorrhage: a pharmacological approach. <i>Journal of Hepatology</i> , 2010 , 52, 946-8	13.4	8
37	207 MELD VS CPS FOR PROGNOSIS IN CIRRHOSIS. RESULTS FROM A MULTICENTRE STUDY. <i>Journal of Hepatology</i> , 2010 , 52, S89	13.4	2
36	Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation. <i>Cochrane Database of Systematic Reviews</i> , 2010 , CD006573		12
35	Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. <i>Journal of Clinical Gastroenterology</i> , 2010 , 44, e87-95	3	35
34	Antiviral therapy for recurrent liver graft infection with hepatitis C virus. <i>Cochrane Database of Systematic Reviews</i> , 2010 , CD006803		19
33	PP-011 Collagen proportionate area: a continuous quantitative of histological collagen has the best correlation with transient elastography. <i>Gut</i> , 2010 , 59, A44.2-A44	19.2	2
32	PTU-058 Histological liver collagen proportionate area predicts decompensation in patients with liver cirrhosis of mixed aetiologies. <i>Gut</i> , 2010 , 59, A72.1-A72	19.2	
31	Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. <i>Seminars in Oncology</i> , 2010 , 37, 89-93	5.5	34
30	Smoking is associated with histological severity in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2010 , 52, 1522-3	11.2	7
29	Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. <i>Liver Transplantation</i> , 2010 , 16, 64-73	4.5	50
28	A novel immunological assay for hepcidin quantification in human serum. <i>PLoS ONE</i> , 2009 , 4, e4581	3.7	62
27	Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. <i>Mediators of Inflammation</i> , 2009 , 2009, 831670	4.3	87
26	Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. <i>Scandinavian Journal of Gastroenterology</i> , 2009 , 44, 6-14	2.4	48
25	Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. <i>American Journal of Transplantation</i> , 2009 , 9, 1725-31	8.7	70
24	Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 947-54	6.1	17
23	Towards a better liver allocation system. <i>Journal of Hepatology</i> , 2009 , 51, 827-8	13.4	3
22	Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines. <i>Journal of Hepatology</i> , 2009 , 51, 1084-5; author reply 1085-6	13.4	12
21	Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. <i>Scandinavian Journal of Gastroenterology</i> , 2009 , 44, 752-9	2.4	40

20	230 SERUM HEPCIDIN LEVELS DEPEND ON AETIOLOGY BUT NOT SEVERITY OF CIRRHOSIS. <i>Journal of Hepatology</i> , 2009 , 50, S93	13.4	3
19	The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2008 , 61, 391-7	5.9	57
18	Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. <i>Scandinavian Journal of Gastroenterology</i> , 2008 , 43, 1128-36	2.4	70
17	Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. <i>Gut</i> , 2008 , 57, 500-6	19.2	36
16	Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 80-9	6.1	56
15	Acute splenic sequestration crisis (ASSC) in an adult patient with beta-thalassemia sickle cell disease: a life-threatening complication. <i>Annals of Hematology</i> , 2008 , 87, 499-500	3	2
14	Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment. <i>Digestive and Liver Disease</i> , 2007 , 39, 490-4	3.3	8
13	Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2007 , 39, 936-42	3.3	37
12	Adipokines and insulin resistance in chronic hepatitis C. <i>Hepatology</i> , 2007 , 46, 2050-1; author reply 2051	11.2	2
11	Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. <i>American Journal of Gastroenterology</i> , 2007 , 102, 634-41	0.7	32
10	First appearance of Crohn's disease following infliximab treatment for spondylarthropathy. <i>Scandinavian Journal of Gastroenterology</i> , 2007 , 42, 784-5	2.4	6
9	Liver transplantation in Greek patients: epidemiological data, morbidity, and mortality of 71 patients from a single center with 6 years of mean follow-up. <i>Transplantation Proceedings</i> , 2007 , 39, 1505-7	1.1	4
8	Acute ischemic injury due to a giant intrahepatic hematoma: A complication of percutaneous liver biopsy. <i>European Journal of Internal Medicine</i> , 2007 , 18, 339-41	3.9	2
7	Pylephlebitis complicating silent diverticulitis. <i>Lancet, The</i> , 2006 , 368, 422	4.0	7
6	The evolving role of leptin and adiponectin in chronic liver diseases. <i>American Journal of Gastroenterology</i> , 2006 , 101, 2629-40	0.7	145
5	Myelodysplastic syndrome presenting as acquired ichthyosis. <i>European Journal of Internal Medicine</i> , 2006 , 17, 368-9	3.9	4
4	Hepatobiliary and pancreatic: spontaneous splenorenal shunts in portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006 , 21, 1214	4	1
3	Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review. <i>Journal of Clinical Rheumatology</i> , 2005 , 11, 326-8	1.1	17

2	A Sustainable Development Goal framework to guide multisectoral action on NAFLD through a societal approach		1
1	Nutritional supplementation for non-alcohol-related fatty liver disease: a network meta-analysis. <i>The Cochrane Library,</i>	5.2	2